This trial is active, not recruiting.

Condition prostate cancer
Sponsor Memorial Sloan Kettering Cancer Center
Collaborator Rockefeller University
Start date April 1990
End date December 2017
Trial size 5290 participants
Trial identifier NCT00578240, 90-040


The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only

Eligibility Criteria

Male participants of any age.

Inclusion Criteria: Men with prostate conditions representing the following disease states: - No Cancer Diagnosis - Clinically Localized Disease - Rising PSA - Clinical Metastases: Noncastrate - Clinical Metastases: Castrate (Testosterone ≤ 50 ng/ml) - Signed informed consent Exclusion Criteria: -Patients without any prostate related problems.

Additional Information

Official title Molecular Studies and Clinical Correlations in Human Prostatic Disease
Principal investigator Susan Slovin, MD
Description The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center.